Adagene

Adagene Equity

The The Equity of Adagene (ADAG) as of Oct 18, 2026 is 35.35 M USD. In the previous year, The Equity was 50.52 M USD — a change of -30.03% (lower).

Equity

35.35 MUSD

YoY

-30.03%

Last updated:

In 2025, Adagene's equity was 35.35 M USD, a -30.03% increase from the 50.52 M USD equity in the previous year.

The Adagene Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-41.03 M USD
Jan 1, 2019
-57.01 M USD
Jan 1, 2020
-89.39 M USD
Jan 1, 2021
156.56 M USD
Jan 1, 2022
83.09 M USD
Jan 1, 2023
70.56 M USD
Jan 1, 2024
50.52 M USD
Jan 1, 2025
35.35 M USD
The Adagene Equity history
YEAREquityYoY
35.35 MUSD-30.03%
50.52 MUSD-28.40%
70.56 MUSD-15.08%
83.09 MUSD-46.93%
156.56 MUSD-275.14%
-89.39 MUSD+56.80%
-57.01 MUSD+38.96%
-41.03 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adagene Stock analysis

What does Adagene do? Adagene Inc., based in Suzhou, China, is a clinical-stage biotechnology company focused on developing monoclonal antibody drugs for cancer treatment. The company operates in the Health Care sector, with its lead candidates ADG126 and ADG116 in phase 1b/2 trials for various cancers, alongside other pipeline products in clinical and preclinical stages. Listed on 9 February 2021, Adagene employs 128 people and is dedicated to advancing innovative therapies for solid tumors and hematologic malignancies. Adagene is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Adagene's Equity

Adagene's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Adagene's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Adagene's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Adagene's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Adagene’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Adagene stock

The Equity of Adagene is 35.35 M USD in 2025.

The Equity of Adagene changed from 50.52 M USD to 35.35 M USD, representing a -30.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Adagene since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Adagene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Adagene

All Key Metrics — Adagene